iX Biopharma Upsizes Placement to $6.7 Million Amid Strong Demand

TigerNews SG

Oct 29

iX Biopharma has successfully raised $6.7 million through a placement, exceeding its initial target of at least $5 million due to robust investor demand.

The placement shares were priced at 10 cents each and drew participation from notable investors, including Lion Global Investors and Ginko-AGT Global Growth Fund.

The pharmaceutical firm, led by Chairman and CEO Eddy Lee—a former senior executive at Genting and Hong Leong—intends to allocate the proceeds toward expanding its presence in the U.S. market, reducing debt, acquiring new equipment, and bolstering general working capital.

The issuance of new shares will increase iX Biopharma's share base by over 7%.

Trading of iX Biopharma shares is set to resume on October 29. The stock last traded at 13 cents, giving the company a market valuation of $112.9 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1156275348"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156275348\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156275348?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 12:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156275348","market":"sg","top_or_hot":-1,"title":"iX Biopharma Upsizes Placement to $6.7 Million Amid Strong Demand","media":"TigerNews SG","content":"\n<p>iX Biopharma has successfully raised $6.7 million through a placement, exceeding its initial target of at least $5 million due to robust investor demand.</p>  \n\n<p>The placement shares were priced at 10 cents each and drew participation from notable investors, including Lion Global Investors and Ginko-AGT Global Growth Fund.</p>  \n\n<p>The pharmaceutical firm, led by Chairman and CEO Eddy Lee—a former senior executive at Genting and Hong Leong—intends to allocate the proceeds toward expanding its presence in the U.S. market, reducing debt, acquiring new equipment, and bolstering general working capital.</p>  \n\n<p>The issuance of new shares will increase iX Biopharma's share base by over 7%.</p>  \n\n<p>Trading of iX Biopharma shares is set to resume on October 29. The stock last traded at 13 cents, giving the company a market valuation of $112.9 million.</p>  \n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>iX Biopharma Upsizes Placement to $6.7 Million Amid Strong Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\niX Biopharma Upsizes Placement to $6.7 Million Amid Strong Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1050470178\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/f17a9a7b68c877792d5e556261e9e709);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">TigerNews SG </p>\n<p class=\"h-time\">2025-10-29 12:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n\n<p>iX Biopharma has successfully raised $6.7 million through a placement, exceeding its initial target of at least $5 million due to robust investor demand.</p>  \n\n<p>The placement shares were priced at 10 cents each and drew participation from notable investors, including Lion Global Investors and Ginko-AGT Global Growth Fund.</p>  \n\n<p>The pharmaceutical firm, led by Chairman and CEO Eddy Lee—a former senior executive at Genting and Hong Leong—intends to allocate the proceeds toward expanding its presence in the U.S. market, reducing debt, acquiring new equipment, and bolstering general working capital.</p>  \n\n<p>The issuance of new shares will increase iX Biopharma's share base by over 7%.</p>  \n\n<p>Trading of iX Biopharma shares is set to resume on October 29. The stock last traded at 13 cents, giving the company a market valuation of $112.9 million.</p>  \n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"42C.SI","symbol_name":"IX生物制药","start_time":0,"source_url":"","article_id":"1156275348","we_media_id":"1050470178","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156275348","pubTimestamp":1761710899,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"TigerNews SG","introduction":"Providing stock market headlines, business news, financials and earnings","home_visible":1,"id":"1050470178","head_image":"https://community-static.tradeup.com/news/f17a9a7b68c877792d5e556261e9e709"},"summary":"iX Biopharma has successfully raised $6.7 million through a placement, exceeding its initial target of at least $5 million due to robust investor demand.    The placement shares were priced at 10...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"42C.SI":"IX生物制药"},"translate_title":"由于需求强劲，iX Biopharma将配售规模扩大至670万美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"42C.SI":1.1},"content_text":"iX Biopharma has successfully raised $6.7 million through a placement, exceeding its initial target of at least $5 million due to robust investor demand.\nThe placement shares were priced at 10 cents each and drew participation from notable investors, including Lion Global Investors and Ginko-AGT Global Growth Fund.\nThe pharmaceutical firm, led by Chairman and CEO Eddy Lee—a former senior executive at Genting and Hong Leong—intends to allocate the proceeds toward expanding its presence in the U.S. market, reducing debt, acquiring new equipment, and bolstering general working capital.\nThe issuance of new shares will increase iX Biopharma's share base by over 7%.\nTrading of iX Biopharma shares is set to resume on October 29. The stock last traded at 13 cents, giving the company a market valuation of $112.9 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}